MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.
about
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.Blocking and randomization to improve molecular biomarker discovery.The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.MicroRNA applications for prostate, ovarian and breast cancer in the era of precision medicine.Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast CancerAssociation of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1.Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a.Dynamic Expression of Novel MiRNA Candidates and MiRNA-34 Family Members in Early- to Mid-Gestational Fetal Keratinocytes Contributes to Scarless Wound Healing by Targeting the TGF-β Pathway.Quantitative assessment of miR34a as an independent prognostic marker in breast cancer.Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness.MiR-34b is associated with clinical outcome in triple-negative breast cancer patientsThe predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis.Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.Prognostic significance of MiR-34a in solid tumors: a systemic review and meta-analysis with 4030 patients.Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasionOpportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.Pathways to breast cancer recurrence.Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expressionIdentifying breast cancer subtype related miRNAs from two constructed miRNAs interaction networks in silico method.Overexpression and clinical significance of MYC-associated zinc finger protein in pancreatic carcinoma.Molecular characterization of exosome-like vesicles from breast cancer cells.MYC associated zinc finger protein promotes the invasion and metastasis of hepatocellular carcinoma by inducing epithelial mesenchymal transitionMicroRNA-34a expression levels in serum and intratumoral tissue can predict bone metastasis in patients with hepatocellular carcinomaElevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress.Transcription factor and microRNA co-regulatory loops: important regulatory motifs in biological processes and diseases.microRNAs: a new class of breast cancer biomarkers.Mir-34: a new weapon against cancer?Molecular mechanisms of breast cancer metastasis by gene expression profile analysis.MiR-34a modulates ErbB2 in breast cancer.miR-34c regulates the permeability of blood-tumor barrier via MAZ-mediated expression changes of ZO-1, occludin, and claudin-5.Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.The prostate cancer-up-regulated Myc-associated zinc-finger protein (MAZ) modulates proliferation and metastasis through reciprocal regulation of androgen receptor.KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.Genetic Variants in the Promoter Region of miR-10b and the Risk of Breast Cancer.DNA/RNA-based formulations for treatment of breast cancer.MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma.Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates with aggressive and advanced breast cancer disease.Genome-wide screen for serum microRNA expression profile in mfat-1 transgenic mice.
P2860
Q30570563-AECAFD5D-664F-44DC-B058-CEDCAC8B8E54Q30582547-57C3EEF4-A1AB-428A-BC9E-AACE20A6DE02Q33618617-1B0672F7-DB29-40F1-986B-5E6E501987FBQ33733403-1B2DD085-9E73-4C97-BA0C-EB09A570075AQ33734951-FD7BEDA0-6EC0-4375-9CF0-ADB8ED1EC0E7Q34088205-31636C6E-BE96-4D60-A6C6-5F44F8AB4380Q34446981-F4FDD315-4569-403B-90A2-BA1621EE7274Q34514418-53E4996E-C2B4-4194-A2D4-F929B45FEE14Q35610932-71A13EA6-E042-431F-97D7-DA95330690EFQ35677744-64142520-7246-48E0-A60C-0FCB54222721Q35833028-58E3AB45-8D05-476D-934A-D6F31923DF76Q35950656-11A2EA1F-DA8B-46DC-80FF-56F02CCC3D6FQ36111707-600A72D5-6C12-4401-AB79-E0EFF9719BB7Q36383057-7EEE181F-F134-40AB-92ED-CABF21EACFBBQ36411504-CAEA7A4C-BF09-4BBE-806D-D02089B11428Q36460483-D0952132-A48E-4B44-8925-2D58ADC310F0Q36589155-BB209414-B134-4035-BA2C-B10182415765Q36702139-C60E21D7-896B-4FDC-A8CC-BF456A4D77ABQ36998944-AED6AEAC-BD33-4C4F-B731-E047277E2239Q37079785-5EA0CB49-D5CA-4B9C-B5EB-5046B881A292Q37369098-4976F232-F971-4436-B1B8-1FF169C15BB8Q37515695-9E1812BC-9E2C-47D6-941A-5EE76E9108CEQ37607048-1FA020F5-74F7-4431-81A1-AFA6DC9DD423Q37699248-E4F776CF-CFB0-454A-956F-81723A5C1453Q37699408-96B338C8-A20A-4F2A-9B11-4677FD24F8A2Q37709040-1FD63A98-578B-4E85-A44E-C2ECF527FF95Q38168821-7D6C04E2-9CEC-4C67-83B3-9FD6CD29B7D5Q38197675-A8440DD4-9038-4D27-A219-BC89D8EC30F3Q38253374-5B611791-50DB-4C66-ABF5-C9339C4A99FEQ38632885-BF41020E-C9DD-4B46-A09E-BFB723C4F3A7Q38733014-B97CC8C1-CA5D-45C0-BEC1-678BE0279745Q38958450-87D2D6E1-A98A-4EE8-9C90-08468410E924Q38970049-5729D1E7-B1FD-4AE5-87AA-A4EB65042B0FQ39162205-B1BD08A3-3CBD-4C7A-908B-CF422AA0B597Q39839292-8B8128EE-2A5C-470B-9146-2A07D99420E5Q40129925-6AF0D674-E5E5-453B-BDBA-9C726416C81DQ40252910-D9422C73-A3D6-4F8D-9F26-5FF5600DB9BFQ41208796-50512171-A2DB-49D0-AB5E-72BA5AC98CECQ44940375-22CB1AB1-14CC-4A8A-9EFB-5D8B628F7DB0Q46873471-0C226442-B7F1-4203-86CC-8A5FE23B53D0
P2860
MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@ast
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@en
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@nl
type
label
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@ast
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@en
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@nl
prefLabel
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@ast
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@en
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@nl
P2093
P2860
P50
P1433
P1476
MiR-34a expression has an effe ...... ical outcome in breast cancer.
@en
P2093
Hanna Peurala
Maral Jamshidi
Päivi Heikkilä
Ralf Bützow
Sippy Kaur
P2860
P304
P356
10.1371/JOURNAL.PONE.0026122
P407
P50
P577
2011-11-10T00:00:00Z